stockrow
Friday 6 November 2026
Export STXS’s income statement to Excel — free account
Stereotaxis Inc.
STXS Healthcare Medical Instruments & Supplies
Stereotaxis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.4 million, up 20.3% from fiscal 2024.
- Revenue
- −12.8%
- EPS
- 0.00%
- Free cash flow
- +0.45%
Quarter to June 2026, against a year earlier
1.04
0.08
+8.33%
Follow STXS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 32 | 31 | 29 | 29 | 27 | 35 | 28 | 27 | 27 | 32 | 30 | +0.1% | 34 | 46 | — | +18.8% | |
| Gross margin, % | 76.59 | 65.47 | 80.52 | 78.77 | 71.22 | 66.34 | 65.62 | 55.51 | 54.22 | 52.73 | 55.57 | (23.9) pt | ||||||
| EBT | (5) | (6) | 0 | (5) | (7) | (11) | (18) | (21) | (24) | (22) | (22) | +17.0% | ||||||
| EBT margin, % | (16.44) | (18.90) | 0.40 | (15.89) | (24.96) | (30.60) | (64.99) | (77.37) | (89.33) | (66.85) | (74.24) | (50.4) pt | ||||||
| Net income | (5) | (6) | 0 | (5) | (7) | (11) | (18) | (21) | (24) | (22) | (22) | +17.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 1.47 | 1.38 | 0.56 | 0.46 | 0.37 | 0.46 | 0.37 | 0.33 | 0.32 | 0.36 | 0.30 | (14.6%) | |||||
| Earnings | (0.54) | (0.32) | (0.03) | (0.10) | (0.11) | (0.16) | (0.26) | (0.27) | (0.30) | (0.25) | (0.24) | (8.2%) | ||||||
| Cash flow | (0.30) | (0.21) | (0.05) | (0.07) | (0.05) | (0.04) | (0.11) | (0.11) | (0.10) | (0.15) | (0.15) | (7.4%) | ||||||
| Capex | (0.02) | 0.00 | (0.01) | 0.00 | 0.00 | (0.02) | (0.03) | 0.00 | 0.00 | 0.00 | 0.00 | (27.8%) | ||||||
| Free cash flow | (0.32) | (0.21) | (0.05) | (0.07) | (0.05) | (0.06) | (0.14) | (0.12) | (0.10) | (0.15) | (0.15) | (8.0%) | ||||||
| Book value | (0.71) | (0.91) | 0.14 | 0.45 | 0.55 | 0.52 | 0.42 | 0.27 | 0.13 | 0.21 | 0.17 | n/m | ||||||
| Shares, m | 22 | 23 | 52 | 63 | 73 | 76 | 76 | 81 | 85 | 91 | 95 | +17.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.47 | 0.61 | 1.92 | 11.54 | 13.90 | 13.38 | 5.67 | 5.64 | 7.22 | 6.46 | 3.46 | 6.7 | ||||||
| P/B | 0.00 | 0.00 | 42.90 | 14.65 | 10.70 | 13.85 | 6.06 | 9.23 | 31.94 | 15.52 | 8.50 | 14.5 | ||||||
| EV/Sales | 0.87 | 1.17 | 2.27 | 10.67 | 12.39 | 12.35 | 4.76 | 5.00 | 6.87 | 6.15 | 3.22 | 6.3 | ||||||
| EV/FCF | (3.94) | (7.66) | (23.67) | (66.39) | (91.78) | (99.59) | (12.42) | (14.08) | (21.69) | (14.44) | (6.24) | (35.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (7) | (5) | (3) | (5) | (4) | (3) | (8) | (9) | (8) | (14) | (15) | +8.5% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | (1) | (2) | 0 | 0 | 0 | 0 | (15.2%) | ||||||
| Free cash flow | (7) | (5) | (3) | (5) | (4) | (4) | (11) | (10) | (9) | (14) | (16) | +7.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (16) | (20) | 8 | 27 | 39 | 38 | 29 | 20 | 5 | 11 | 11 | n/m | |||||
| Net debt | (9) | (4) | (11) | (28) | (43) | (39) | (29) | (20) | (12) | (13) | (10) | +5.2% | ||||||
| Shareholders’ equity | (16) | (21) | 7 | 29 | 40 | 39 | 32 | 22 | 11 | 19 | 17 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (59.23) | (46.28) | (9.03) | (19.39) | (16.19) | (20.72) | (34.33) | (46.28) | (57.21) | (46.30) | (48.76) | +12.9 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | (698.34) | 0.00 | (3,457.08) | (394.59) | (865.53) | 0.00 | (260.75) | (203.58) | (260.7) pt | ||||||
| ROE | 60.34 | 30.46 | 10.43 | (50.02) | (27.94) | (35.24) | (65.26) | (103.35) | (226.13) | (234.28) | (344.36) | (294.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 120 | 117 | 119 | 118 | 120 | 130 | 130 | 122 | 139 | 131 | — | +1.0% | |||||
| Revenue/emp, $m | 0.27 | 0.27 | 0.25 | 0.24 | 0.22 | 0.27 | 0.22 | 0.22 | 0.19 | 0.25 | — | (0.9%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Stereotaxis Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| UTMD Utah Medical Products, Inc. | $202.4M | 21.7× | 28.7× | −14.31% (below 0%: shrinking) | −10.64% (below 0%: shrinking) | −55.74% (below 0%: shrinking) | 55.79% | 31.06% | Compare |
| PDEX Pro-Dex, Inc. | $195.8M | 16.4× | 18.8× | +10.96% (above 0%: growing) | −33.57% (below 0%: shrinking) | +177.76% (above 0%: growing) | 33.35% | 17.10% | Compare |
| KRMD KORU Medical Systems, Inc. | $139.9M | — (loss-making) | — (loss-making) | +18.15% (above 0%: growing) | n/m | +26.17% (above 0%: growing) | 65.14% | 5.21% | Compare |
| STXS Stereotaxis Inc. | $105.2M | — (loss-making) | — (loss-making) | −12.82% (below 0%: shrinking) | n/m | +0.45% (above 0%: growing) | 58.49% | (59.56%) | |
| ZTEKF Zentek Ltd. | $62.3M | — (loss-making) | — | −95.36% (below 0%: shrinking) | n/m | −254.61% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| POCI Precision Optics Corp. | $54.3M | — (loss-making) | — (loss-making) | +41.95% (above 0%: growing) | n/m | −45.64% (below 0%: shrinking) | 25.34% | (1.21%) | Compare |
| DXR Daxor Corporation | $50.4M | 4.0× | 7.6× | −27.62% (below 0%: shrinking) | n/m | −88.56% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| HBIO Harvard Bioscience, Inc. | $38.5M | — (loss-making) | — (loss-making) | +11.13% (above 0%: growing) | n/m | −123.43% (below 0%: shrinking) | 55.57% | (4.30%) | Compare |
| DAVI Davion Healthcare PLC | $32.8M | — | — | — | — | — | — | — | Compare |
| Median of peers | $58.3M | 16.4× | 18.8× | +10.96% | — | −55.74% | 33.35% | 0.00% |
Pay and ownership Proxy statement filed 3 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 64.39k | (2.04m) | 111.11 |
| 2024 | 62.20k | 3.72m | 112.08 |
| 2023 | 62.20k | (4.29m) | 84.54 |
Ownership
Directors and executive officers, together
16.03%
Nathan Fischel, M.D.
14.33%
DAFNA Capital Management, LLC
14.07%
Joseph Kiani Dynasty Trust
9.99%
2012 Revocable Trust of Andrew Redleaf
7.77%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement